Learn more →
Back to Expert Scholars
thoracic-oncology / thoracic-oncologyGlobal NSCLC Access and Targeted Therapy

Natasha B. Leighl

娜塔莎·莱尔

MD, MMSc, FRCPC

🏢Princess Margaret Cancer Centre / University of Toronto(玛格丽特公主癌症中心 / 多伦多大学)🌐Canada

Medical Oncologist; Professor of Medicine肿瘤内科医生;医学教授

55
h-index
3
Key Papers
4
Awards
3
Key Contributions

👥Biography 个人简介

Dr. Natasha Leighl is a global lung cancer leader known for research on targeted therapy access, liquid biopsy, and NSCLC outcomes in diverse populations. She has led international clinical trials and advocates for equitable cancer care worldwide.

Share:

🧪Research Fields 研究领域

Thoracic Oncology胸部肿瘤学
NSCLC非小细胞肺癌
Global Access to Targeted Therapy靶向治疗全球可及性
Liquid Biopsy液态活检

🎓Key Contributions 主要贡献

Global Access to Lung Cancer Therapy

Pioneered research on barriers to targeted therapy access in low- and middle-income countries, quantifying disparities and proposing policy solutions to improve NSCLC outcomes globally.

Liquid Biopsy Clinical Implementation

Led prospective studies demonstrating feasibility and clinical utility of plasma EGFR testing in routine NSCLC care, supporting guideline recommendations for non-invasive molecular testing.

International NSCLC Clinical Trials

Principal and co-investigator on numerous global EGFR and immunotherapy trials, contributing to evidence base for treatment of diverse NSCLC populations including Asian and elderly patients.

Representative Works 代表性著作

[1]

Plasma ctDNA as a Theranostic Platform in Non-Small Cell Lung Cancer

JAMA Oncology (2019)

Demonstrated prospective clinical utility of plasma EGFR testing in guiding first-line treatment decisions, supporting broader adoption of liquid biopsy.

[2]

Economic Analysis of Molecular Testing and Targeted Therapy in Advanced NSCLC

Journal of Clinical Oncology (2012)

Quantified cost-effectiveness of EGFR mutation testing, providing health economic justification for universal molecular profiling in lung cancer.

[3]

Erlotinib as Initial Treatment for Patients with Advanced EGFR-Mutation Positive NSCLC

Journal of Clinical Oncology (2010)

Contributed to Canadian perspective on first-line erlotinib efficacy, informing national treatment guidelines and access policy.

🏆Awards & Recognition 奖项与荣誉

🏆Canadian Cancer Society Research Award
🏆ASCO Merit Award
🏆IASLC Women in Thoracic Oncology Award
🏆University of Toronto Department of Medicine Research Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 娜塔莎·莱尔 的研究动态

Follow Natasha B. Leighl's research updates

留下邮箱,当我们发布与 Natasha B. Leighl(Princess Margaret Cancer Centre / University of Toronto)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment